Computational Prediction of Neutralization Epitopes Targeted by Human Anti-V3 HIV Monoclonal Antibodies

被引:8
|
作者
Shmelkov, Evgeny [1 ]
Krachmarov, Chavdar [2 ]
Grigoryan, Arsen V. [1 ]
Pinter, Abraham [2 ]
Statnikov, Alexander [3 ]
Cardozo, Timothy [1 ]
机构
[1] NYU, Sch Med, Dept Biochem & Mol Pharmacol, New York, NY 10003 USA
[2] Rutgers New Jersey Med Sch, Publ Hlth Res Inst Ctr, Newark, NJ USA
[3] NYU, Sch Med, Ctr Hlth Informat & Bioinformat, New York, NY USA
来源
PLOS ONE | 2014年 / 9卷 / 02期
基金
美国国家卫生研究院;
关键词
IMMUNODEFICIENCY-VIRUS TYPE-1; BROAD NEUTRALIZATION; CROSS-REACTIVITY; STRUCTURAL BASIS; BINDING MODE; VACCINE; GP120; COMPLEX; DESIGN; CONFORMATION;
D O I
10.1371/journal.pone.0089987
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The extreme diversity of HIV-1 strains presents a formidable challenge for HIV-1 vaccine design. Although antibodies (Abs) can neutralize HIV-1 and potentially protect against infection, antibodies that target the immunogenic viral surface protein gp120 have widely variable and poorly predictable cross-strain reactivity. Here, we developed a novel computational approach, the Method of Dynamic Epitopes, for identification of neutralization epitopes targeted by anti-HIV-1 monoclonal antibodies (mAbs). Our data demonstrate that this approach, based purely on calculated energetics and 3D structural information, accurately predicts the presence of neutralization epitopes targeted by V3-specific mAbs 2219 and 447-52D in any HIV-1 strain. The method was used to calculate the range of conservation of these specific epitopes across all circulating HIV-1 viruses. Accurately identifying an Ab-targeted neutralization epitope in a virus by computational means enables easy prediction of the breadth of reactivity of specific mAbs across the diversity of thousands of different circulating HIV-1 variants and facilitates rational design and selection of immunogens mimicking specific mAb-targeted epitopes in a multivalent HIV-1 vaccine. The defined epitopes can also be used for the purpose of epitope-specific analyses of breakthrough sequences recorded in vaccine clinical trials. Thus, our study is a prototype for a valuable tool for rational HIV-1 vaccine design.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1
    Armstrong, SJ
    McInerney, TL
    McLain, L
    Wahren, B
    Hinkula, J
    Levi, M
    Dimmock, NJ
    JOURNAL OF GENERAL VIROLOGY, 1996, 77 : 2931 - 2941
  • [22] Resistance of Subtype C HIV-1 Strains to Anti-V3 Loop Antibodies
    Almond, David
    Krachmarov, Chavdar
    Swetnam, James
    Zolla-Pazner, Susan
    Cardozo, Timothy
    ADVANCES IN VIROLOGY, 2012, 2012
  • [23] A BROADLY REACTIVE HUMAN ANTI-V3 MONOCLONAL-ANTIBODY EFFECTIVELY NEUTRALIZES PRIMARY HIV-1 ISOLATES
    GORNY, M
    WILLIAMS, C
    ZOLLAPAZNER, S
    OSSORIO, M
    BANSAL, G
    KOENIG, S
    CONLEY, AJ
    KESSLER, JA
    BOOTS, LJ
    LINEBERGER, D
    SCHLEIF, WA
    EMINI, EA
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1994, 10 : S34 - S34
  • [24] Cross-neutralizing activity of human anti-V3 monoclonal antibodies derived from non-B clade HIV-1 infected individuals
    Andrabi, Raiees
    Williams, Constance
    Wang, Xiao-Hong
    Li, Liuzhe
    Choudhary, Alok K.
    Wig, Naveet
    Biswas, Ashutosh
    Luthra, Kalpana
    Nadas, Arthur
    Seaman, Michael S.
    Nyambi, Phillipe
    Zolla-Pazner, Susan
    Gorny, Miroslaw K.
    VIROLOGY, 2013, 439 (02) : 81 - 88
  • [25] Human Anti-V3 HIV-1 Monoclonal Antibodies Encoded by the VH5-51/VL Lambda Genes Define a Conserved Antigenic Structure
    Gorny, Miroslaw K.
    Sampson, Jared
    Li, Huiguang
    Jiang, Xunqing
    Totrov, Maxim
    Wang, Xiao-Hong
    Williams, Constance
    O'Neal, Timothy
    Volsky, Barbara
    Li, Liuzhe
    Cardozo, Timothy
    Nyambi, Phillipe
    Zolla-Pazner, Susan
    Kong, Xiang-Peng
    PLOS ONE, 2011, 6 (12):
  • [26] ANTI-V3 ANTIBODIES FAIL TO INHIBIT CELL-TO-CELL TRANSMISSION OF HIV-1
    DEMAREST, JF
    PANTALEO, G
    ZOLLAPAZNER, S
    BANSAL, G
    KOENIG, S
    FAUCI, AS
    JOURNAL OF IMMUNOLOGY, 1993, 150 (08): : A317 - A317
  • [27] Production and characterization of human anti-V3 monoclonal antibodies from Indian clade C human immunodeficiency virus type-1 (HIV-1) infected patients
    Andrabi, R.
    Kurnar, R.
    Bala, M.
    Nair, A.
    Biswas, A.
    Wig, N.
    Kumar, P.
    Luthra, K.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2012, 15 : 2 - 2
  • [28] Worldwide epitope prevalence of crystallographically resolved anti-V3 antibodies
    Swetnam, J.
    Zolla-Pazner, S.
    Cardozo, T. J.
    RETROVIROLOGY, 2009, 6
  • [29] HIV-1 Neutralization Coverage Is Improved by Combining Monoclonal Antibodies That Target Independent Epitopes
    Doria-Rose, Nicole A.
    Louder, Mark K.
    Yang, Zhongjia
    O'Dell, Sijy
    Nason, Martha
    Schmidt, Stephen D.
    McKee, Krisha
    Seaman, Michael S.
    Bailer, Robert T.
    Mascola, John R.
    JOURNAL OF VIROLOGY, 2012, 86 (06) : 3393 - 3397
  • [30] Immunoglobulin Gene Usage by Neutralizing Human Anti-V3 HIV-1 Monoclonal Antibodies Derived from Clade B and Non-B HIV-1 Infected Individuals
    Gorny, M. K.
    Wang, X.
    Jiang, X.
    Williams, C.
    Volsky, B.
    Revesz, K.
    Witover, B.
    Krachmarov, C.
    Pinter, A.
    Nadas, A.
    Zolla-Pazner, S.
    Kong, X.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2008, 24 : 46 - 46